home>medemsa>project-areas.html Seite teilen:

MeDeMSA Project areas

Early diagnosis of MSA

We anticipate to carve out a set of diagnostic tests that reliably diagnose MSA at early stages. Apart from prospectively validating well-established diagnostic biomarkers, the bio-specimen banking will grant us the opportunity to develop future disease-specific fluid markers.

PD Dr. Florian Krismer, MD, PhD and Dr. Frank Jagusch, MD

Personalized best medical care in MSA

We will establish models for patient-centered, multidisciplinary medical care for people with MSA. By integrating telemedicine and mobile palliative care, we aim at abating the barriers between wheelchair-bound people with MSA and their specialists, securing continuity of care towards the end of life.

Assist. Prof.ⁱⁿ Dr.ⁱⁿ Alessandra Fanciulli, MD, PhD

Prof. Gregor K. Wenning, MD, PhD, MSc

HTA supported medical decisions in MSA

Decision-analytic models applied to key aspects of MSA clinical practice in PA4 will inform health-care decision makers on the benefit-harm balance and cost-effectiveness of test-treatment strategies for MSA.

Von links: Assoc.-Prof.ⁱⁿ, PD - Dr.ⁱⁿ Beate Jahn, PhD - Dr.ⁱⁿ Marjan Arvandi, MSc, PhD - Prof. Uwe Siebert, MD, MPH, MSc, ScD - Prof.ⁱⁿ Daniela Schmid, PhD, MSc

Ethical and regulatory aspects in MSA

This Project area will translate available questionnaires for determining health-care goals and caregiver’s burden into German, customize them to the setting of MSA and make them available to the scientific community. The results of PA5 will be used to i. address the unmet need of a bioethical codex for patient-centered medical decisions in MSA and ii. develop educational material, which will help physicians counsel MSA patients and their care-givers in advanced care planning (ACP) matters. We anticipate that the structured implementation of ethical aspects in MSA clinical practice will contribute to improve the QoL of people with MSA and the communication with their physicians, ultimately increasing their autonomy in the decision-making process and capability for ACP and end of life decisions.

Von links: Prof.ⁱⁿ Martina Schmidhuber, PhD und Dr.ⁱⁿ Caroline Breitegger, MD